NCT02871219View on ClinicalTrials.gov

Obinutuzumab and Lenalidomide in Treating Patients With Previously Untreated Stage II-IV Grade 1-3a Follicular Lymphoma

PHASE2CompletedINTERVENTIONAL
Enrollment

96

Participants

Timeline

Start Date

December 6, 2016

Primary Completion Date

June 26, 2024

Study Completion Date

June 26, 2024

Conditions
Ann Arbor Stage II Grade 1 Follicular LymphomaAnn Arbor Stage II Grade 2 Follicular LymphomaAnn Arbor Stage III Grade 1 Follicular LymphomaAnn Arbor Stage III Grade 2 Follicular LymphomaAnn Arbor Stage IV Grade 1 Follicular LymphomaAnn Arbor Stage IV Grade 2 Follicular LymphomaBulky DiseaseFatigueFeverGrade 3a Follicular LymphomaNight SweatsSplenomegalyWeight Loss
Interventions
DRUG

Lenalidomide

Given PO

BIOLOGICAL

Obinutuzumab

Given IV

Trial Locations (1)

77030

M D Anderson Cancer Center, Houston

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

M.D. Anderson Cancer Center

OTHER

NCT02871219 - Obinutuzumab and Lenalidomide in Treating Patients With Previously Untreated Stage II-IV Grade 1-3a Follicular Lymphoma | Biotech Hunter | Biotech Hunter